1. Introduction
Cyclodextrins (CD) are cyclic oligosaccharides composed of 6, 7 and 8 glucopyranose units which form a hydrophobic cavity with a hydrophilic surface. This structure is able to complex poorly soluble active pharmaceutical ingredients (API) and in most of cases can increase their permeability through biological barriers [
1,
2,
3]. In addition to intermolecular forces between the host cyclodextrin and guest drug determined by the hydrophobicity of the guest molecule, the functional groups on the cyclodextrin and the derivatives with larger structures containing several cyclodextrins can significantly modify the complex-forming ability of carriers. The hydroxyl groups of the cyclodextrin ring at the C2, C3 and C6 positions are reactive, and the modification of the hydroxyl groups can help the extensive application of cyclodextrins in pharmaceutical development [
4,
5,
6,
7].
Cyclodextrin polymers offer new opportunities to broaden the scope of usability of drug delivery systems. [
8]. The polymer structure may increase the possibility of the molecular interactions between the CD cavity and drug molecules [
9]. Depending on the reaction conditions, it is possible to create soluble or insoluble polymers with the same reagents. The most common cross-linkers are epichlorohydrin, citric acid, and bifunctionalized activated acids as less toxic cross-linkers [
3,
8,
10,
11]. Whereas the main application of water soluble cyclodextrin polymers has been the solubilization of poorly soluble drugs [
12,
13,
14,
15], the insoluble types have been used mostly as a sorbent to remove pollution from contaminated water and to concentrate the analytes in analytical chemistry [
9,
16,
17,
18], although some human studies with insoluble polymers were also conducted in the early 1980s [
19]. The size and shape of insoluble cyclodextrins affects their physical and biological properties also. The cyclodextrin polymers prepared in different shapes (pearl, foil, fiber or block) such as cyclodextrin beads were patented by Cyclolab in 1981 [
20]. These beads were prepared by cross-linking with epichlorohydrin in the presence of polyvinyl alcohol, and the manufacturing process resulted in a regular spherical shape. In 1996 the insoluble CDP was modified with ionic groups and it was proved that the carboxymethyl polymer is a good sorbent for cationic API and the degree of carboxymethylation controlled the drug release [
21]. In the same year Felméray et al. published on the wound healing ability of cyclodextrin polymer [
22]. With the emerging green synthesis methods, the mechanochemical synthesis of cyclodextrin derivatives such as the cyclodextrin polymers was invented, and a solid, insoluble, β-cyclodextrin polymer (βCDPIS) was cross-linked with epichlorohydrin, such that the cyclodextrin microbeads were prepared in a planetary ball mill, under solventless conditions [
23]. Due to the lack of the heterogeneous phases, the shape of the particles is irregular, and amorphous.
Despite the great potential drug carrier abilities of insoluble cyclodextrin polymers, there are limited numbers of studies which investigate this topic. By not being dissolved in the medium, their advantage can be the formation of a reservoir matrix. Compared to conventional matrix systems, these are smaller and contain the active ingredients in a molecularly dispersed/complexed manner. Furthermore, by complexing the active ingredient, they also have the benefits of cyclodextrins, thereby increasing the stability of the active ingredients, protecting the active ingredient from degradation or gastric acid damage, and being able to mask flavors and odors. Based on these assumptions, our aim was to study and compare the properties and the reservoir usability of βCDPIS and β-cyclodextrin microbeads (βCDPB) as micro-size, controlled drug delivery systems. For this purpose, two water-insoluble model drugs, curcumin (water solubility 3.12 mg/L) [
24] and estradiol (water solubility 3.9 mg/L) [
25] were used, and their complexation, liberation and biocompatibility were tested. The novelty of this work is that the insoluble cyclodextrin polymers had not yet been compared and tested systematically, and the results obtained reveal the possible application of the insoluble cyclodextrin matrix systems for oral drug delivery.
2. Materials and Methods
2.1. Materials
The solid insoluble β-cyclodextrin polymer of irregular shape (βCDPIS) was synthesized at University of Turin (Turin, Italy), as reported earlier. Briefly at the first step, CD-sodium was formed, then epichlorohydrin cross-linking was performed. Reactions were carried out in a planetary ball mill (Retsch PM100 High Speed Planetary Ball Mill, Retsch GmbH, Haan, Germany), using a 50 mL stainless steel jar and mix of stainless steel balls (m = 44.1 g, in which ø = 5 mm, m = 28.1 g and 550 ø = 1–1.2 mm, m = 16.0 g) at 650 rpm [
23,
26]. Cyclodextrin microbeads (βCDPB) were made by Cyclolab Ltd. (Budapest, Hungary, Prod. No.: CY-2011). βCDP is prepared by cross-linking of βCD with epichlorohydrin in water, using NaOH as base, in the presence of polyvinyl alcohol at 70–80 °C [
20,
22]. This results in regular spherical beads of 0.1–0.3 mm diameter. Estradiol-glow (17-β-estradiol labeled with a low molecular weight biocompatible fluorophore) (
Figure 1) was ordered from Jena Bioscience, and curcumin and the other reagents were from Sigma-Aldrich Ltd. (Budapest, Hungary).
2.2. Physical Properties of Insoluble Cyclodextrin Polymers
2.2.1. Size Distribution
The samples were fixed on microscope slides by Fluoromount Aqueous Mounting Medium or in paraffin oil to prevent the moving of polymer, and were observed with a Zeiss AxioScope.A1 fluorescence microscope (HBO 100 lamp) (Carl Zeiss Microimaging GmbH, Göttingen, Germany). The average diameter of the particles was calculated by measuring the diameter of 20 particles by the help of ZEN 2012 v.1.1.0.0 software (Carl Zeiss Microimaging GmbH, Göttingen, Germany).
2.2.2. Scanning Electron Microscopy (SEM)
Surface area exploration used a Hitachi Tabletop microscope (TM3030 Plus, Hitachi High-Technologies Corporation, Tokyo, Japan) in high-resolution mode. The samples were attached to a fixture with a double-sided adhesive tape containing graphite. Before SEM examination gold-sputtered coating was not deposited on the surface of the samples, as the instrument is suitable for the direct investigation of the specimens without any surface pre-treatments. The measurement requires a vacuum and low, 5kV accelerating voltage. Magnifications were 60×, 250×, 500× and 15,000×.
2.2.3. Swelling Capacity
An Enslin device (manufactured in-house) was used to determine the swelling properties of polymers in three types of medium, namely 30% ethanol, 10% DMSO and water (pH 6.5) [
27,
28]. In ethanol and DMSO solutions, the swelling capacity plays an important role in complex formation, while swelling in water is also associated with drug release in the human body. Samples (100 mg) were placed on a filter of the apparatus and the volume of absorbed water was read at specific time points at 10, 20, 30, 60, 120, 180, 240, 300, 360, 480, 600 and 900
s. Swelling capacity of polymers was expressed by the volume of water uptake per gram of polymer (mL/g).
2.3. Complexation Properties of Insoluble Cyclodextrin Polymers
2.3.1. Complexation Study and Preparation of Complexes
To study the complexation of the cyclodextrin polymers with the applied APIs, curcumin and estradiol-glow were precisely measured and dissolved in 96% ethanol and pure DMSO, respectively, to create 1 mM stock solutions. These solutions were diluted with water and the applied solvents to reach the final concentrations of APIs (10, 40, 100, 200 µM) in 30% ethanol or 10% DMSO solutions, respectively. For the complexation study, 20 mg insoluble cyclodextrin polymer carriers were added to the solutions, and the suspensions were stirred at room temperature up to 24 h for the formation of complexes (βCDPIS-est, βCDPB-est, βCDPIS-cur, βCDPB-cur). After centrifugation (5000 rpm, 10 min), the API content of supernatants were determined by UV-VIS (curcumin λ
abs = 430 nm, Shimadzu UV-1900 spectrophotometer, Kyoto, Japan) and fluorescence spectroscopy (estradiol-glow λ
exc = 544 nm, λ
em = 612 nm; FLUOstar OPTIMA microplate reader BMG LABTECH, Offenburg, Germany), and the complexed amount of APIs were calculated. Loading efficiency was calculated from the extraction curve of API by the following method [
29]:
Preparation of complexes: for further experiments, 200 µM API solutions were used to create complexes with the method described above. After the complexation process, the sedimented parts, namely the complexes, were freeze-dried using a freeze drier, and the complex were kept in a freezer at −20 °C. The API loading capacity was calculated by the following equation:
2.3.2. FTIR Analysis
The FTIR ATR spectra experiments were performed on a PerkinElmer Spectrum Two instrument (LiTaO3 detector, diamond window) by Spectrum IR v10.2 software, using 64 scans at 1 cm
−1 resolution of 0.25 cm
−1 data collection interval. Corrections of environmental CO
2 and H
2O used the software’s built-in method. Evaluation of spectra used SpectraGryph 1.2.16d software (Software for optical spectroscopy by Dr. Friedrich Menges, Oberstdorf, Germany,
http://spectroscopy.ninja (accessed on 15 January 2021)).
2.3.3. Powder X-ray Diffraction (PXRD)
To analyze the crystal form of APIs and polymers, physical mixtures and freeze-dried complexes were prepared, and ultrapure API was used as a control. The finely powdered sample was fixed onto a Mitegen MicroMeshes sample holder (MiTeGen Co., Ithaca, NY, USA) with a minimal amount of oil. Powder diffraction data of the samples with Debye Scherer geometry were collected using a Bruker-D8 Venture (Bruker AXS. GmbH, Karlsruhe, Germany) diffractometer equipped with INCOATEC IμS 3.0 dual (Cu and Mo) sealed tube micro sources (50 kV, 1.4 mA). A Photon 200 Charge-integrating Pixel Array detector and CuKα (λ = 1.54178 Å) radiation was applied. Several frames were collected with various detector-sample distances in phi scan mode. Data collection and integration was performed using the APEX3 and DiffracEva software (Bruker AXS Inc., Madison, WI, USA, Version 4.2.2.3), respectively.
2.3.4. Thermoanalytical Methods (TGA/DSC)
The thermal analysis (thermogravimetric analysis-TGA and differential scanning calorimeter-DSC) of the samples was carried out with a Mettler-Toledo TGA/DSC1 instrument (Mettler-Toledo GmbH, Greifensee, Switzerland). Quantities between 3 mg and 10 mg of samples were placed in a closed aluminum crucible (Mettler-Toledo GmbH, Greifensee, Switzerland) with a volume of 40 μL. The temperature range was between 25–500°C, and the applied heating rate was 10°C/min. Nitrogen atmosphere was used (cell gas: 50 mL/min, method gas: 70 mL/min). With the objective of comparing the curves, the results were normalized to sample weight and the evaluation of the curves was acquired with STARe Software (Mettler-Toledo GmbH, Greifensee, Switzerland).
2.4. MTT (3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) Assay
The cytotoxic effects of cyclodextrin carriers were evaluated using MTT test. Caco-2 cells were seeded in 96-well plates at a density of 10,000 cells/well. After 3 days, the medium was removed, and the cells were incubated for 30 min with the suspensions of carriers (0–25.0 mg/mL). The samples were then removed, and a 0.5 mg/mL MTT (3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) solution (in phosphate-buffered saline—PBS) was added to each well. The plates were incubated for 3 h at 37 °C, then the MTT solution was removed and 0.1 mL isopropanol:1 M hydrochloride acid (25:1) was added to each well to dissolve the formed formazan crystals. The absorbance of dissolved formazan was measured at 570 nm and the background was measured at 690 nm by Thermo-Fisher Multiskan Go (Thermo-Fisher, Waltham, MA, USA) microplate reader.
2.5. In Vitro Dissolution Test
A modified dissolution test was elaborated for the investigation of the dissolution of APIs from the polymer carriers due to the small amount of samples and the low water solubility of curcumin and estradiol. An amount of 20 mg complex was suspended in 1.5 mL of fetal bovine serum (FBS), which was applied as the dissolution medium in the tests. The experiments were performed at 37 °C with continuous shaking at 100 rpm. Samples of 0.50 mL were withdrawn after 15 min, 30 min, 60 min and 120 min. Three parallel measurements were performed with each complex, and the released amount of curcumin and estradiol was determined by the following method.
In the case of curcumin, samples were purified from protein by adding acetonitrile to the samples (2:1 volume ratio). The obtained solutions were analyzed using a HPLC system (Merck-Hitachi ELITE with photodiode array detector (DAD)). The column was an Agilent HC-C18(2) (150 × 4.6 mm), kept at 40 °C, and the DAD was set at 430 nm. The mobile phase was acetonitrile and 2% acetic acid solution (4:6), and 1.0 mL flow rate was used. The analyses were performed with EZChrom Elite software TM (Hitachi, Tokyo, Japan), which was also used for collecting and processing the data. 10 μL standard solution and purified samples were injected.
Estradiol was measured directly from the dissolution medium by fluorescence spectroscopy (estradiol-glow λexc = 544 nm, λem = 612 nm; FLUOstar OPTIMA microplate reader BMG LABTECH, Offenburg, Germany).
2.6. In Vitro Permeability Study
In vitro permeability studies used Transwell® polycarbonate filters (area: 1.12 cm2, pore size: 0.4 µm) (Corning, Glendale, Arizona, USA ) to grow Caco-2 monolayers. Studies were started with the initial seeding of 250,000 cells/transwell and when the transepithelial electrical resistance (TEER) reached 300 Ωcm2, the monolayers were used in the permeability experiments. Samples of complexes of 20 mg each, made by complexation with 200 µM API solutions, were dispersed in Fetal Bovine Serum (FBS) and placed on the apical surface of the monolayers. During the experiments, the basal chamber also contained FBS. Control samples were treated with only estradiol-glow or curcumin, respectively.
In the case of estradiol-glow, samples were taken from the basal sides of the cell layers at specific time points (0,5 h, 1 h, 2 h, 4 h, 8 h, and 24 h) and the permeated amount of estradiol-glow was measured with the fluorescence microplate reader method as mentioned above.
In some permeability experiments, the estradiol-glow cellular uptake was examined by the following method. Caco-2 cells were previously seeded onto sterile round glass coverslips and placed under cell-free Transwell® polycarbonate filters, during the permeability experiments. In this study, we sought to examine whether estradiol-glow is able to reach the cellular target after liberation and by free diffusion from the insoluble complex, and can accumulate in the more lipophilic intracellular environment. After 2 h of the test, cells were washed with Hank’s Balanced Salt Solution (HBSS) fixed with 3% paraformaldehyde solution, and cell nuclei were stained in 300 nM 4′,6-Diamidino-2-phenylindole dihydrochloride (DAPI) solution at room temperature for 15 min. Finally, the samples were mounted onto glass microscopic slides. The uptake of estradiol-glow was investigated by fluorescence microscopy using a Zeiss Axioscope A1 fluorescence microscope (HBO 100 lamp) (Carl Zeiss Microimaging GmbH, Göttingen, Germany) with the following filters: DAPI: excitation G 365 nm, emission BP 445/50 nm; and estradiol-glow: excitation BP 546/12 nm, emission BP 575–640 nm. PBS without estradiol-glow was used as negative control.
In the case of curcumin permeability studies, after 24 h of incubation of monolayers with the complexes, samples from the basal chambers were collected and analyzed as described in
Section 2.5.
The apparent permeability coefficient (P
app) of chrysin was calculated using the following equation [
30]:
where P
app is the apparent permeability coefficient (cm/s);
dQ/
dt is the permeability rate of substances (mol/s);
C0 is the initial concentration of the substances in the upper compartment (mol/mL); and
A is the surface area of the membrane (cm
2).
2.7. Statistical Analysis
Mean values of different groups were compared by one way ANOVA using SigmaStat 3.5 software (Systat Software, Inc., San Jose, CA, USA). Data are presented as means ± SD, and differences were considered significant at p < 0.05.
4. Discussion
In the last few years, more and more studies have been published on cyclodextrin polymers. Some of these have researched water-insoluble ones, but most of them focused on their application in environmental protection. Our aim was to investigate two insoluble cyclodextrin polymers of similar structure as drug carriers, which can be considered also as reservoir matrix systems. Due to their particle size and water insoluble nature, their most adequate application could be that of oral drug administration carrying APIs of low solubility or poor absorption from the gastrointestinal tract. We chose two chemically different model substances to test their interactions with βCDPIS and βCDPB. Both curcumin and estradiol are administered orally, having low solubility; and curcumin also has poor absorption and bioavailability [
39]. Both polymers were prepared by cross-linking βCD with epichlorohydrin, but under different conditions. The traditional two-phase reaction was used to prepare βCDPB applying toxic solvents which are carefully removed during a laborious purification step, or a solventless green technology is applied for the production of βCDPIS. Although their chemical nature is similar, the size and shape of particles shows large differences: the beads are bigger than βCDPIS particles. The latter is produced by ball milling where the simultaneous synthesis and milling results in obviously small particle size. The βCDPB has a smooth surface and spherical shape, while the βCDPIS particles are rugged and irregular. The porous structure of the bead is non-visible at the applied magnification, and it has the ability to swell several times its weight probably because of the hydrophilic network structure. The bead polymer absorbs 4–5 times their weight from water and aqueous solutions (e.g., biological liquids) [
22]. The βCDPIS showed lower swelling due to a more cross-linked structure [
26]. Comparing the swelling capacity of beads, it is less in both 30% ethanol and 10% DMSO than in water; while βCDPIS swelled the most efficiently in 10% DMSO, although there was no high difference in the swelling in the studied solvents. The preparation of the beads by the traditional emulsion method results in dihydroxypropyl side-chains due to the partial hydrolysis of the cross-linking epichlorohydrin. The extra hydroxyl groups in theses dihydroxypropyl side chains cause enhanced hydrophilicity and enhanced swelling in more hydrophilic solvents. In the solventless preparation of βCDPIS, hydrolysis hardly occurs, resulting in more cross-linked structures of lower hydrophilicity and reduced swelling (
Figure 13).
The better swelling of beads caused higher loading efficiency for the curcumin complexation, shown by the higher affinity of curcumin to microbeads. The opposite trend for estradiol-glow can be attributed to the less hydrophilic character of the network. Both APIs selected for these studies form 2:1 host:guest complexes. They were selected to utilize the close proximity of the CD rings able to cooperatively bind these guest molecules. Postulating that both carriers have approximately the same cyclodextrin content, the differences can be explained by the different accessibility of the cyclodextrin cavities and by the different properties of the network. The secondary cavities formed by the network contribute to the binding of the two model APIs to a different extent [
9].
In this study, a very simple complexation method was applied to the insoluble polymers, which were incubated with the solutions of APIs, the drug molecules were captured by the carriers during continuous mixing, and the complexes were separated by centrifugation from the free molecules in solution. As an alternative separation method, filtration or centrifugal filtration can also be applied. This process does not require the evaporation of the bulk solvent after complexation (freeze-drying or spray-drying usually applied for complexes of monomer cyclodextrins): only the wet product should be dried. In addition to the energy- and time-saving properties, the complexation process can be easily standardized after the determination of the loading efficiency and loading capacity of an API. To optimize the loading efficiency, the different complexation abilities of the carriers should be taken into account.
On the other hand, it is well-known that complexation of a small molecule with cyclodextrins causes a significant mass increment of the formulation due to the high molecular weight of cyclodextrins. This is especially true for cyclodextrin polymers and therefore, for oral formulations, APIs with low effective doses are required. Estradiol is suitable to fulfill this requirement as its oral dose is around 1 mg.
The biocompatibility of the cyclodextrin polymer carriers was tested by MTT test. The data show that the polymers were not toxic to Caco-2 intestinal cells after 30 min of incubation. The observed biocompatibility is in accordance with the results of Szejtli et al. whose published research show that the beads could help with wound healing and cell growth at a specified concentration [
24].
The dissolution test of APIs shows that both curcumin and estradiol liberated from the complexes, but this is strongly influenced by the type of polymer. The liberated amount of APIs was low, but it should be noted that the solubility of both APIs in water is very low. We tested different dissolution buffers, but it was not possible to dissolve the APIs and obtain a concentration which is suitable for analysis. The best solution was the application of FBS, which was able to keep the APIs in solution and dissolve the molecules from the insoluble complexes. Polymer carriers did not increase the apparent permeability (Papp) of APIs through the Caco-2 cell monolayers compared to the controls. It should be mentioned that Papp shows the speed of penetration, which is strongly affected by the speed of dissolution from the carriers. Indeed, Papp trend of APIs inversely correlated with the loading efficiency of complexes, but showed a relationship with the dissolution profiles. Lower loading efficiency caused by weaker interactions between the polymers and APIs caused better dissolution and higher Papp values. These observations are true for both curcumin and estradiol. In other words, carriers with lower affinity caused higher permeation, while carriers with higher affinity delayed the permeation of APIs. In both cases the permeability was lower than the control solution probably due to the retention of APIs by the polymers. As the dissolution of APIs was low from the carriers, we sought to demonstrate that estradiol was able to liberate from the insoluble complexes and reach the cellular target only by free diffusion. The results of cellular uptake studies confirmed that, though the dissolution of estradiol from the carriers was limited, complexation does not inhibit its liberation; that it reached the cellular target; and that it accumulated in the more lipophilic intracellular environment.
Taking the results together, the insoluble β-cyclodextrin polymers are suitable drug carriers for oral formulations, and the appropriate type of carrier can be fitted to the different APIs. There are two major factors which strongly influence the success of application. The first is the strength of interaction of polymers with APIs, which should be optimal for the binding and liberation of APIs. The second is the therapeutical dose of API, which should be low for the preparation of applicable oral formulations. From this point of view, estradiol is a more suitable API for a formulation with an insoluble cyclodextrin polymer carrier. The potential continuation of this work could be the design of a reservoir system that may be beneficial in the development of inhalation, subcutaneous, or possibly dermal formulations. Insoluble cyclodextrin polymers keep the drug molecularly dispersed, which protects it from environmental influences and provides a slow release from the matrix. This may be beneficial in the above-mentioned therapeutic systems.